Drug intelligence / Profile preview

DermaPro

Development stage: Unknown
Lead developer: DermaTools Biotech
Administration: Topical, Oral

Overview

DermaPro is an active substance developed by DermaTools Biotech, a subsidiary of CytoTools (now BioXXmed), for the treatment of wound healing indications. It is currently undergoing clinical development for ulcus cruris in Europe and is being prepared for clinical trials in the USA for the same indication. Additionally, it has undergone Phase II/III trials for diabetic foot ulcers in India through a partnership with Centaur Pharmaceuticals.

Brand names: DermaPro

Beyond the preview

Go deeper on DermaPro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermaPro.

Explore the full profile